{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:33:45Z","timestamp":1791614025590,"version":"4.3.4"},"reference-count":39,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2022,5]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>Posttherapy measurable residual disease (MRD) positivity in core binding factor acute myeloid leukemia (CBF\u2010AML) is associated with shorter relapse\u2010free survival (RFS). Elimination of MRD measured via quantitative reverse transcription polymerase chain reaction (qRTPCR) for disease specific transcripts can potentially lead to better outcomes in CBF\u2010AML.<\/jats:p><\/jats:sec>Methods<\/jats:title>We prospectively monitored the MRD<\/jats:styled-content> using qRTPCR<\/jats:styled-content> and flow cytometry on bone marrow samples in patients with newly diagnosed CBF\u2010AML<\/jats:styled-content> who received decitabine (DAC<\/jats:styled-content>) maintenance therapy after fludarabine\/cytarabine\/G\u2010CSF<\/jats:styled-content> (FLAG<\/jats:styled-content>)\u2010based induction\/consolidation regimen. Negative qRTPCR<\/jats:styled-content> (CMR<\/jats:styled-content>) was defined as fusion transcript <0.01%.<\/jats:p><\/jats:sec>Results<\/jats:title>Thirty\u2010one patients with CBF\u2010AML<\/jats:styled-content> including 14 with t(8;21) and 17 with inv(16) received parenteral DAC as maintenance therapy. Fifteen patients (48.3%) had completed FLAG<\/jats:styled-content>\u2010based induction\/consolidation but with positive MRD<\/jats:styled-content> (0.35%, range\u00a0=\u00a00.01%\u20130.91%) (Group 1). Sixteen patients (51.7%) could not complete recommended consolidations with FLAG<\/jats:styled-content>\u2010based regimen (due to older age or complications) and were switched to DAC maintenance (Group 2). In Group 2, eight patients (50%) had undetectable MRD<\/jats:styled-content> (Group 2A<\/jats:styled-content>) (all had qRTPCR<\/jats:styled-content> \u2264 0.01%) and the other eight patients (50%) had residual fusion product by qRTPCR<\/jats:styled-content> (0.1%, range\u00a0=\u00a00.02%\u20130.36%) (Group 2B<\/jats:styled-content>) prior to starting DAC. Amongst the 23 patients who had a PCR<\/jats:styled-content> \u2265 0.01% before maintenance therapy (Groups 1 and 2B<\/jats:styled-content>), 12 patients (52%) attained a CMR<\/jats:styled-content> as their best response (responders). The median pre\u2010DAC qRTPCR<\/jats:styled-content> amongst responders were 0.03% compared to 0.14% in nonresponders (p<\/jats:italic>\u00a0=\u2009.002). The median estimated molecular RFS amongst responders were 93.9\u2009months. At a median follow\u2010up of 59.3\u2009months (13.2\u2013106\u2009months) from DAC<\/jats:styled-content> initiation, 16 patients (51.6%) had to be initiated on a second line of therapy (40%, 25%, and 100% patients, respectively, in Groups1, 2A,<\/jats:styled-content> and 2B<\/jats:styled-content>). The median estimated time to new treatment between responders was 112.4 versus 5.8\u2009months in nonresponders (hazard ratio\u00a0=\u00a00.16, 95% confidence interval\u00a0=\u00a00.04\u20130.54); however, there were no difference in overall survival between these groups (p<\/jats:italic>\u00a0=\u2009.37).<\/jats:p><\/jats:sec>Conclusion<\/jats:title>DAC is an effective maintenance therapy for CBF\u2010AML<\/jats:styled-content> patients with persistent fusion transcript at a low level after FLAG<\/jats:styled-content>\u2010based regimen. Attainment of CMR<\/jats:styled-content> with DAC<\/jats:styled-content> maintenance can lead to long\u2010term remission in patients who have persistent MRD<\/jats:styled-content> positive after FLAG<\/jats:styled-content>\u2010based regimen or are unable to receive the full course of consolidation therapy.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ajh.26496","type":"journal-article","created":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T12:54:22Z","timestamp":1644670462000},"page":"574-582","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia"],"prefix":"10.1002","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6831-2567","authenticated-orcid":false,"given":"Jayastu","family":"Senapati","sequence":"first","affiliation":[{"name":"Department of Leukemia the University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahran","family":"Shoukier","sequence":"additional","affiliation":[{"name":"Department of Leukemia the University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-2482","authenticated-orcid":false,"given":"Guillermo","family":"Garcia\u2010Manero","sequence":"additional","affiliation":[{"name":"Department of Leukemia the University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-9832","authenticated-orcid":false,"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[{"name":"Department of Leukemia the University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-377X","authenticated-orcid":false,"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"Department of Leukemia the University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-6513","authenticated-orcid":false,"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[{"name":"Department of Leukemia the University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1689-4470","authenticated-orcid":false,"given":"Maro","family":"Ohanian","sequence":"additional","affiliation":[{"name":"Department of Leukemia the University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[{"name":"Department of Leukemia the University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney","family":"DiNardo","sequence":"additional","affiliation":[{"name":"Department of Leukemia the University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesid","family":"Alvarado","sequence":"additional","affiliation":[{"name":"Department of Leukemia the University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Aldrich","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7679-6453","authenticated-orcid":false,"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[{"name":"Department of Leukemia the University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,2,22]]},"reference":[{"issue":"18","key":"e_1_2_8_2_1","first-page":"4173","article-title":"Frequency of prolonged remission duration after high\u2010dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype","volume":"58","author":"Bloomfield CD","year":"1998","journal-title":"Cancer Res"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3767"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.11.006"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00503-6"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23927"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126014"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.15.610"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24367"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.09.017"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402478"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-435669"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2017.021675"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2005.08.030"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0158-1"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.131946"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.09.020"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402159"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404015"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.112"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1681"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-126227"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.252"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.153"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24782"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403135"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.88"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.093765"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2107-z"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.180"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-688705"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2341"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-462879"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32769"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.0617"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.4874"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0146614"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2016.08.005"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26496","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.26496","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26496","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T17:37:40Z","timestamp":1692812260000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.26496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1002\/ajh.26496"],"URL":"https:\/\/doi.org\/10.1002\/ajh.26496","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,22]]},"assertion":[{"value":"2021-12-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}